|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||
2 August 2005 | Volume 143 Issue 3 | Pages 199-211
Background: The association of body mass index and gastroesophageal reflux disease (GERD), including its complications (esophagitis, Barrett esophagus, and esophageal adenocarcinoma), is unclear.
Purpose: To conduct a systematic review and meta-analysis to estimate the magnitude and determinants of an association between obesity and GERD symptoms, erosive esophagitis, Barrett esophagus, and adenocarcinoma of the esophagus and of the gastric cardia.
Data Sources: MEDLINE search between 1966 and October 2004 for published full studies.
Study Selection: Studies that provided risk estimates and met criteria on defining exposure and reporting outcomes and sample size.
Data Extraction: Two investigators independently performed standardized search and data abstraction. Unadjusted and adjusted odds ratios for individual outcomes were obtained or calculated for each study and were pooled by using a random-effects model.
Data Synthesis: Nine studies examined the association of body mass index (BMI) with GERD symptoms. Six of these studies found statistically significant associations. Six of 7 studies found significant associations of BMI with erosive esophagitis, 6 of 7 found significant associations with esophageal adenocarcinoma, and 4 of 6 found significant associations with gastric cardia adenocarcinoma. In data from 8 studies, there was a trend toward a doseresponse relationship with an increase in the pooled adjusted odds ratios for GERD symptoms of 1.43 (95% CI, 1.158 to 1.774) for BMI of 25 kg/m2 to 30 kg/m2 and 1.94 (CI, 1.468 to 2.566) for BMI greater than 30 kg/m2. Similarly, the pooled adjusted odds ratios for esophageal adenocarcinoma for BMI of 25 kg/m2 to 30 kg/m2 and BMI greater than 30 kg/m2 were 1.52 (CI, 1.147 to 2.009) and 2.78 (CI, 1.850 to 4.164), respectively.
Limitations: Heterogeneity in the findings was present, although it was mostly in the magnitude of statistically significant positive associations. No studies in this review examined the association between Barrett esophagus and obesity.
Conclusion: Obesity is associated with a statistically significant increase in the risk for GERD symptoms, erosive esophagitis, and esophageal adenocarcinoma. The risk for these disorders seems to progressively increase with increasing weight.
The notion of obesity as a cause of GERD is biologically plausible. Obesity has been associated with increased intra-abdominal pressures (15), impaired gastric emptying (16), decreased lower esophageal sphincter pressure, and increased frequency of transient sphincter relaxation (17, 18), thus leading to increased esophageal acid exposure. However, the epidemiologic evidence linking obesity to GERD and its complications has not been critically reviewed. We aimed to evaluate, quantify, and summarize the association of obesity to GERD and its complications.
Two investigators independently searched the published English-language literature (through October 2004) by using MEDLINE. Search terms included obesity or body mass or anthroprometry searched with reflux or heartburn, (o)esophagitis, Barrett's or Barretts, and (o)esophageal cancer or (o)esophageal adenocarcinoma. We performed a recursive hand search of cited bibliographies to increase completeness.
Study Selection Criteria
The following inclusion criteria had to be fulfilled: 1) cross-sectional, casecontrol, or cohort study that permitted assessment of a causal association between overweight or obesity and esophageal disease; 2) clear definition of obesity as defined by a body mass index (BMI) in kg/m2 or height-to-weight ratio; and 3) well-defined outcome of interest that included GERD symptoms defined by using validated symptom score, esophageal erosions defined by endoscopy, and Barrett esophagus or esophageal adenocarcinoma validated by pathology review. We excluded case reports and case series, studies with fewer than 50 case-patients, and studies that did not report risk estimates or raw data to allow independent calculation of these estimates. If a study met the selection criteria except for failure to report risk estimates, we contacted the study authors in an attempt to obtain these data.
Statistical Analysis
We abstracted or calculated odds ratios for cross-sectional and casecontrol studies and risk ratios for cohort studies as the risk estimates for associations between obesity and each outcome of interest. We pooled the results in 2 different ways. All studies either presented or had sufficient information to allow the calculation of unadjusted odds ratios estimates (and 95% CIs). We subsequently pooled these unadjusted estimates. Because of the inconsistency in reporting adjusted risk estimates, we estimated the degree of confounding produced by uncontrolled variables in studies that did not report adjusted risk estimates by using a factorization of the relative risk by external adjustment (19). Subsequently, we pooled the adjusted estimates. In addition, we displayed the adjusted odds ratios in a tabular form, indicating the variables that were adjusted for. We conducted pooling by using a random-effects model. We examined the weighted pooled risk estimates for 2 recognized categories: overweight and obesity (20, 21). We assessed heterogeneity with a chi-square test and by visual inspection of Forest plots. We performed statistical analyses with Comprehensive Meta-Analysis (Biostat, Englewood, New Jersey) and Stata 8.0 (Stata Corp., College Station, Texas). We examined funnel plots to evaluate for publication bias.
We identified 370 potentially relevant titles. Of these, 9 studies satisfied our inclusion and exclusion criteria (22-30). All studies were cross-sectional examinations of GERD symptoms in randomly selected samples of the general population (Table 1). Only 3 studies (Nilsson and colleagues [(29], Murray and colleagues [28], and Lagergren and colleagues [26]) were conducted for the primary purpose of evaluating the relationship between obesity and GERD. REVIEW
Meta-Analysis: Obesity and the Risk for Gastroesophageal Reflux Disease and Its Complications
Frequent symptoms of gastroesophageal reflux disease (GERD) affect between 10% and 20% of adults in the United States. The prevalence of GERD-related complications, including erosive esophagitis, Barrett esophagus, and esophageal adenocarcinoma, has been steadily increasing in the United States and western Europe. For instance, hospitalizations with GERD among veterans increased 10-fold from the 1970s to the 1990s (1). Similarly, the incidence of esophageal adenocarcinoma increased 4-fold over the past 20 years (2-5). The reasons for the increase in GERD and its complications are not known. Changes in diet, prescription medication use, smoking, and alcohol intake and the declining prevalence of Helicobacter pylori infection have been proposed (6-11). Studies have also hypothesized that the increasing trend of obesity in western populations has paralleled the increase in esophageal adenocarcinoma and may be an important factor in this change (12-14).
Methods
![]()
Top
Methods
Results
Discussion
Author & Article Info
References
Literature Search
Results
![]()
Top
Methods
Results
Discussion
Author & Article Info
References
GERD Symptoms
|
Of the 9 studies, 6 studies showed a statistically significant association between obesity and GERD (23-25, 28-30), and 3 studies showed no association (22, 26, 27). Eight of the studies presented data to allow for calculation of unadjusted and adjusted odds ratios and 95% CIs for GERD, overweight (BMI, 25 kg/m2 to 30 kg/m2), and obesity (BMI > 30 kg/m2). In these 8 studies, the pooled weighted unadjusted odds ratios for GERD symptoms among overweight and obese persons were 1.5- and 2.0-fold, respectively, greater than normal-weight persons (Figure 1; Appendix Figure 1).
|
|
Table 1 presents the adjusted odds ratios. Seven studies adjusted for age and sex. Two studies adjusted for race (24, 27), 3 studies adjusted for nonsteroidal anti-inflammatory drug intake (23, 28, 30), 5 studies adjusted for cigarette smoking (23, 26, 28-30), 1 study adjusted for H. pylori status and socioeconomic status (28), and 1 study adjusted for physical activity (26). None of these adjustments changed the statistical significance or direction of the observed associations. Similarly, adjustments for alcohol (23, 26, 28-30), coffee consumption (23, 28-30), or other dietary factors (such as dietary fiber [29] or total energy intake [26]) resulted in no appreciable changes in the odds ratios. Nilsson and colleagues (29) found that adjustment for postmenopausal hormone therapy in women strengthened the association.
Two studies (Andersen and Jensen [22] and Stanghellini [25]) did not adjust for confounding factors. On the basis of findings from the studies that provided both adjusted and unadjusted odds ratios, we estimated the effect of confounding variables to reduce the unadjusted ratio by a factor of 0.13, which we applied to the 2 studies. The pooled adjusted odds ratios were 1.43 (95% CI, 1.158 to 1.774; P = 0.001) for BMI of 25 kg/m2 to 30 kg/m2 and 1.94 (CI, 1.468 to 2.566; P < 0.001) for BMI greater than 30 kg/m2 (Figure 1). The heterogeneity among the results of these studies was statistically significant (chi-square, 82.1; P < 0.001).
Erosive Esophagitis
Our search identified 111 potentially relevant titles. Of these, 7 studies (4 casecontrol studies [31-34], 2 cross-sectional studies [35, 36], and 1 cohort study [37]) fulfilled the inclusion and exclusion criteria (Table 2). Three studies (Wilson and colleagues [33], Stene-Larson and colleagues [32], and Nilsson and colleagues [31]) were conducted for the primary purpose of evaluating the relationship between obesity and esophagitis.
|
We calculated a pooled odds ratio for the 4 casecontrol and 2 cross-sectional studies, excluding the 1 cohort study by Ruhl and Everhart (37). The pooled unadjusted odds ratio of esophagitis related to BMI of 25 kg/m2 or higher was 1.7-fold greater than that of esophagitis related to BMI less than 25 kg/m2 (Appendix Figure 2). When we excluded the 2 studies from Asia (35, 36) from our analysis, the association between obesity and esophagitis did not appreciably change (pooled unadjusted odds ratio, 1.8 [CI, 1.5 to 2.2]) and there was no statistical heterogeneity (chi-square, 0.15; P > 0.2).
|
|
Barrett Esophagus
No studies reporting the association of Barrett esophagus and obesity met the selection criteria of our review.
Esophageal Adenocarcinoma and Adenocarcinoma of the Gastric Cardia
Our search strategy identified 93 titles. Of these, 9 casecontrol studies met the inclusion and exclusion criteria. Eight studies examined population-based samples, and 1 study examined hospital-based samples (38). Four studies (Chow and colleagues [(39], Ji and colleagues [40], Zhang and colleagues [41], and Lagergren and colleagues [42]) were conducted for the primary purpose of evaluating the relationship between obesity and esophageal adenocarcinoma.
The studies of Chow and colleagues (39), Lagergren and colleagues (42), Vaughan and colleagues (43), and Wu and colleagues (44) examined esophageal adenocarcinoma as a separate category from gastric cardia adenocarcinoma. Cheng and colleagues (45) excluded cancer of the cardia but may have included cancer of the gastroesophageal junction. Brown and colleagues (46) and Zhang and colleagues (41) combined data for adenocarcinomas of the esophagus with the gastric cardia. The 2 studies from China included only cases of gastric cardia adenocarcinoma (38, 40).
Because substantial weight loss at the time of cancer diagnosis was a concern, all studies, except 1 study (38), obtained historical weight information. Among the 3 studies that collected several historical heights and weights (39, 42, 44), the magnitude or direction of the association between BMI at different time points and risk for adenocarcinoma did not statistically significantly differ.
Esophageal Adenocarcinoma
Seven studies examined the association between obesity and esophageal adenocarcinoma (Table 3). Weighted pooling of unadjusted odds ratios (Appendix Figure 3) indicates that the risk for esophageal adenocarcinoma is 2.1 times higher in persons with BMI of 25 kg/m2 or greater than in normal-weight persons. We did not include Zhang and colleagues' study (41) in the pooled odds ratio because the study combined cases of both esophageal and gastric cardia cancer.
|
|
All studies adjusted for age and sex, and these were not found to have any appreciable effect on the association. Further adjustments for race (41, 43, 44), smoking (39-46), alcohol consumption (40-43, 45, 46), caloric intake (40-42, 45, 46), history of reflux symptoms (42, 45), or education level (40-44) did not alter the statistical significance or direction of unadjusted associations. The pooled adjusted odds ratio from 6 studies for BMI of 25 kg/m2 or greater was 2.02 (CI, 1.534 to 2.669; P < 0.001). There was a trend toward a doseresponse relationship with an increase in pooled adjusted odds ratio for BMI of 25 kg/m2 to 30 kg/m2 and BMI greater than 30 kg/m2 of 1.52 (CI, 1.147 to 2.009; P = 0.004) Figure 3, top) and 2.78 (CI, 1.850 to 4.164; P < 0.001) Figure 3, bottom).
|
Adenocarcinoma of the Gastric Cardia
Six studies examined the association of obesity and adenocarcinoma of the gastric cardia (Table 3). Four studies showed a statistically significant association (Table 3). Vaughan and colleagues (43) showed an association that did not reach statistical significance. One study from China by Zhang and colleagues (38) showed a statistically significant inverse association. We pooled unadjusted estimates from 5 studies (Figure 3 and Appendix Figure 3) with a modest, weighted pooled odds ratio of 1.5. In general, adjustment resulted in an increase in the odds ratios by a factor of 0.3. We applied this factor to derive adjusted odds ratios in studies that provided only unadjusted estimates. The pooled adjusted odds ratio from all 6 studies was 1.68 (CI, 1.197 to 2.351; P = 0.003). These results had statistically significant heterogeneity (chi-square, 45.3; P < 0.001). However, the 1 study with an inverse association examined BMI 1 year before the cancer diagnosis, whereas other studies used more distant BMI. Excluding that study reduced the heterogeneity (chi-square, 7.6; P = 0.1). Finally, funnel plots were not suggestive of publication bias (not shown).
Discussion
|
|---|
|
|
|---|
We did not provide a quality score for the individual studies included in our review. However, our inclusion and exclusion criteria ensured a minimum standard of quality. Thus, all studies used acceptable definitions of exposure (BMI) and outcomes of interest (symptoms, endoscopic findings, and pathologic confirmation). Most studies that examined symptoms and cancer were population-based studies with acceptable enrollment rates. However, only 10 of 25 studies stated that the primary purpose of the study was to examine the relationship between obesity and GERD. Another limitation that particularly applies to casecontrol studies evaluating adenocarcinoma is recall bias, where case-patients may overestimate their historical weight compared with noncancer controls. However, the consistency across studies provides some reassurance against recall bias. To minimize the possibility of recall bias, 3 studies examined patients with squamous-cell carcinoma of the esophagus (39, 42, 43) and 4 studies examined patients with distal gastric adenocarcinoma (38-40, 44) as a second cancer comparison group. These studies found that BMI had either no association or a statistically significant negative association with the cancer controls. Furthermore, in all erosive esophagitis studies, BMI was measured directly.
The heterogeneity test indicated statistically significant degrees of heterogeneity among studies. However, the association between BMI and GERD complications was markedly consistent, and differences in the risk estimates were largely in the magnitude rather than the direction of the association. No studies had a negative association, and the 4 studies with no significant association indicated a trend toward statistical significance. Therefore, the use of pooled odds ratios was appropriate. In the case of esophagitis, the heterogeneity was largely attributed to geographic differences among the study samples. Removing studies that were conducted in Asia eliminated heterogeneity among studies of esophagitis.
Overweight and obesity satisfy several criteria for a causal association with GERD and its complications, including esophagitis and esophageal adenocarcinoma. Our review indicates a consistent modest statistical association, a correct temporal relationship, and possibly a weak doseresponse relationship. However, estimates of BMI in most studies were obtained for several years predating the outcomes. The cross-sectional and casecontrol design of most studies makes it difficult to be emphatic about temporal association, especially for chronic slowly progressive conditions, such as GERD symptoms and erosive esophagitis.
Obese patients may experience extrinsic gastric compression by surrounding adipose tissue, leading to an increase in intragastric pressures and subsequent relaxation of the lower esophageal sphincter (47-49). The findings of manometric studies, however, have been inconsistent, indicating both decreased (50) and normal (17, 51-53) lower esophageal sphincter pressures in obese persons.
Studies have also suggested that rather than obesity, the amount and type of dietary intake, notably fat, are responsible for GERD. Seven studies in our review examined total caloric intake and dietary intake of fiber, fruits and vegetables, or other macronutrients or micronutrients. In all, the effect of BMI on GERD-related disorders was independent of dietary intake, which is further supported by a recent smaller study (54). Moreover, all studies found no consistent association between dietary fat and GERD or esophageal adenocarcinoma.
Obese patients may have an increased risk for hiatal hernia, which has a role in initiating and promoting GERD (55). In our review, 3 studies specifically examined hiatal hernia in relation to obesity and GERD or esophagitis (27, 32, 33). Wilson and colleagues (33) found obesity to be statistically significantly associated with esophagitis. However, after the authors controlled for the presence of hiatal hernia, this association lost statistical significance, implying that hiatal hernia was the mechanism by which obesity leads to esophagitis. Wu and colleagues (44), on the other hand, found no statistically significant association between BMI and hiatal hernia. In a study that examined the association of BMI and grade of esophagitis in persons with esophagitis, El-Serag and Johanson (56) also found that obesity remained an independent risk factor for severe versus mild esophagitis while controlling for the presence of hiatal hernia. The cross-sectional nature of these studies makes it impossible to distinguish temporal associations between obesity and hiatal hernia. In sum, data about hiatal hernia as a cause of increased esophageal reflux in obesity are conflicting.
Humoral factors have also been considered as a mechanism relating obesity to reflux and esophageal adenocarcinoma. Two studies identified in our review conducted by the same group of investigators from Sweden observed that the association of obesity and GERD might be mediated by estrogen (29, 31). The first study reported a statistically significant association between obesity and esophagitis in women, which was potentiated by the use of estrogen in postmenopausal women (31). The second study examined a large population-based cohort and found that obese women had an increased risk for GERD symptoms compared with obese men; the risk was highest in premenopausal women and postmenopausal women receiving estrogen therapy (29). Furukawa and colleagues (36) reported that overweight women older than 70 years of age were the only group to have a statistically significantly increased risk for esophagitis. The authors did not report on estrogen use in these patients. However, several other studies have found that the obesity-related increased risk for esophageal disease was neither confounded nor modified by sex (27, 56).
Some evidence suggests that a change in weight can also affect the risk for GERD and its complications. For example, Nilsson and colleagues (29) found that a weight gain greater than 3.5 kg/m2 was associated with a 2.7-fold (CI, 2.3- to 3.2-fold) increased risk for developing new reflux symptoms. On the other hand, although weight loss is often recommended as a therapeutic measure in reflux disease (57), the studies yielded conflicting results on its efficacy (58, 59). Small nonrandomized studies suggest that weight loss after bariatric surgery for morbid obesity is associated with an improvement in GERD symptoms (60, 61). Finally, no data suggest that weight loss can affect risk for esophageal adenocarcinoma.
The mechanism of obesity-related esophageal adenocarcinoma is unclear. Of interest, no studies satisfying our inclusion and exclusion criteria assessed the association between obesity and Barrett esophagus. Excluded because of the absence of a control group, Caygill and colleagues' study (62) reported a BMI greater than 30 kg/m2 in 24% of patients in their case series of 102 patients with Barrett esophagus, as compared with an obesity prevalence of 13% in the general population of England. Excluded because of few cases, a casecontrol study by Chak and colleagues (63) and a cross-sectional study by Gerson and colleagues (64) both reported no apparent increase in risk for obesity in 35 and 27 patients with Barrett esophagus, respectively, although Chak and colleagues reported that the duration of obesity was statistically significantly longer in patients with Barrett esophagus.
Our review suggests that overweight and obesity are risk factors for acid-related esophageal disease. Future studies should examine the mechanism by which obesity causes these complications, as well as the potential effects of weight loss. In the meantime, however, it is prudent to counsel all overweight patients who present with GERD-related diseases that weight loss may help improve symptoms.
Author and Article Information
|
|---|
|
|
|---|
Acknowledgments: The authors thank Loralee Capistrano, MPH, and Jennifer R. Kramer, PhD, for their help in using STATA.
Grant Support: Dr. El-Serag is a recipient of the Department of Veterans Affairs Health Services Research and Development Advanced Career Development Award (RCD00-013-2).
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Hashem B. El-Serag, MD, MPH, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard (152), Houston, TX 77030; e-mail, hasheme{at}bcm.tmc.edu.
Current Author Addresses: Drs. Hampel, Abraham, and El-Serag: Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard (152), Houston, TX 77030.
References
|
|---|
|
|
|---|
1. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut. 1998;43:327-33. [PMID: 9863476].
2. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol. 1999;26:2-8. [PMID: 10566604].[Medline]
3. Lagergren J. [Increased incidence of adenocarcinoma of the esophagus and cardia. Reflux and obesity are strong and independent risk factors according to the SECC study]. Lakartidningen. 2000;97:1950-3. [PMID: 10826353].[Medline]
4. Polednak AP. Trends in incidence rates for obesity-associated cancers in the US. Cancer Detect Prev. 2003;27:415-21. [PMID: 14642548].[Medline]
5. El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002;50:368-72. [PMID: 11839716].
6. Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol. 2000;95:3374-82. [PMID: 11151864].[Medline]
7. Lagergren J, Bergström R, Adami HO, Nyrén O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med. 2000;133:165-75. [PMID: 10906830].
8. Pandolfino JE, Kahrilas PJ. Smoking and gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2000;12:837-42. [PMID: 10958210].[Medline]
9. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ. 2003;326:737 [PMID: 12676842].
10. Sharma P, Vakil N. Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther. 2003;17:297-305. [PMID: 12562442].[Medline]
11. Terry P, Lagergren J, Wolk A, Nyrén O. Reflux-inducing dietary factors and risk of adenocarcinoma of the esophagus and gastric cardia. Nutr Cancer. 2000;38:186-91. [PMID: 11525596].[Medline]
12. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-53. [PMID: 9827707].[Medline]
13. Wei JT, Shaheen N. The changing epidemiology of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14:112-27. [PMID: 14653411].[Medline]
14. El-Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am. 2002;31:421-40. [PMID: 12134611].[Medline]
15. Barak N, Ehrenpreis ED, Harrison JR, Sitrin MD. Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. Obes Rev. 2002;3:9-15. [PMID: 12119661].[Medline]
16. Maddox A, Horowitz M, Wishart J, Collins P. Gastric and oesophageal emptying in obesity. Scand J Gastroenterol. 1989;24:593-8. [PMID: 2762759].[Medline]
17. O'Brien TF Jr. Lower esophageal sphincter pressure (LESP) and esophageal function in obese humans. J Clin Gastroenterol. 1980;2:145-8. [PMID: 7440948].[Medline]
18. Orlando RC. Overview of the mechanisms of gastroesophageal reflux. Am J Med. 2001;111(Suppl 8A):174S-177S. [PMID: 11749946].[Medline]
19. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30. [PMID: 3678409].[Medline]
20. Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology. 1993;4:218-28. [PMID: 8512986].[Medline]
21. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol. 1990;132:612-28. [PMID: 2144946].
22. Andersen LI, Jensen G. Risk factors for benign oesophageal disease in a random population sample. J Intern Med. 1991;230:5-10. [PMID: 2066710].[Medline]
23. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med. 1999;106:642-9. [PMID: 10378622].[Medline]
24. Oliveria SA, Christos PJ, Talley NJ, Dannenberg AJ. Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn. Arch Intern Med. 1999;159:1592-8. [PMID: 10421282].
25. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl. 1999;231:20-8. [PMID: 10565620].[Medline]
26. Lagergren J, Bergström R, Nyrén O. No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study. Gut. 2000;47:26-9. [PMID: 10861260].
27. Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer. 2003;98:940-8. [PMID: 12942560].[Medline]
28. Murray L, Johnston B, Lane A, Harvey I, Donovan J, Nair P, et al. Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol. 2003;32:645-50. [PMID: 12913045].
29. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003;290:66-72. [PMID: 12837713].
30. Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, Locke GR 3rd, Rodriguez-Artalejo F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther. 2004;19:95-105. [PMID: 14687171].[Medline]
31. Nilsson M, Lundegårdh G, Carling L, Ye W, Lagergren J. Body mass and reflux oesophagitis: an oestrogen-dependent association? Scand J Gastroenterol. 2002;37:626-30. [PMID: 12126237].[Medline]
32. Stene-Larsen G, Weberg R, Frøyshov Larsen I, Bjørtuft O, Hoel B, Berstad A. Relationship of overweight to hiatus hernia and reflux oesophagitis. Scand J Gastroenterol. 1988;23:427-32. [PMID: 3381064].[Medline]
33. Wilson LJ, Ma W, Hirschowitz BI. Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol. 1999;94:2840-4. [PMID: 10520831].[Medline]
34. Labenz J, Jaspersen D, Kulig M, Leodolter A, Lind T, Meyer-Sabellek W, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol. 2004;99:1652-6. [PMID: 15330897].[Medline]
35. Chang CS, Poon SK, Lien HC, Chen GH. The incidence of reflux esophagitis among the Chinese. Am J Gastroenterol. 1997;92:668-71. [PMID: 9128320].[Medline]
36. Furukawa N, Iwakiri R, Koyama T, Okamoto K, Yoshida T, Kashiwagi Y, et al. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. J Gastroenterol. 1999;34:441-4. [PMID: 10452674].[Medline]
37. Ruhl CE, Everhart JE. Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Followup Study. First National Health and Nutrition Examination Survey. Ann Epidemiol. 1999;9:424-35. [PMID: 10501410].[Medline]
38. Zhang J, Su XQ, Wu XJ, Liu YH, Wang H, Zong XN, et al. Effect of body mass index on adenocarcinoma of gastric cardia. World J Gastroenterol. 2003;9:2658-61. [PMID: 14669307].[Medline]
39. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90:150-5. [PMID: 9450576].
40. Ji BT, Chow WH, Yang G, McLaughlin JK, Gao RN, Zheng W, et al. Body mass index and the risk of cancers of the gastric cardia and distal stomach in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 1997;6:481-5. [PMID: 9232333].[Abstract]
41. Zhang ZF, Kurtz RC, Sun M, Karpeh M Jr, Yu GP, Gargon N, et al. Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. Cancer Epidemiol Biomarkers Prev. 1996;5:761-8. [PMID: 8896886].[Abstract]
42. Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130:883-90. [PMID: 10375336].
43. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1995;4:85-92. [PMID: 7742727].[Abstract]
44. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control. 2001;12:721-32. [PMID: 11562112].[Medline]
45. Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mozaffari P, et al. A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer. 2000;83:127-32. [PMID: 10883680].[Medline]
46. Brown LM, Swanson CA, Gridley G, Swanson GM, Schoenberg JB, Greenberg RS, et al. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst. 1995;87:104-9. [PMID: 7707381].
47. Mercer CD, Rue C, Hanelin L, Hill LD. Effect of obesity on esophageal transit. Am J Surg. 1985;149:177-81. [PMID: 3966634].[Medline]
48. Mercer CD, Wren SF, DaCosta LR, Beck IT. Lower esophageal sphincter pressure and gastroesophageal pressure gradients in excessively obese patients. J Med. 1987;18:135-46. [PMID: 3480930].[Medline]
49. Zacchi P, Mearin F, Humbert P, Formiguera X, Malagelada JR. Effect of obesity on gastroesophageal resistance to flow in man. Dig Dis Sci. 1991;36:1473-80. [PMID: 1914772].[Medline]
50. Hagen J, Deitel M, Khanna RK, Ilves R. Gastroesophageal reflux in the massively obese. Int Surg. 1987;72:1-3. [PMID: 3596968].[Medline]
51. Backman L, Granström L, Lindahl J, Melcher A. Manometric studies of lower esophageal sphincter in extreme obesity. Acta Chir Scand. 1983;149:193-7. [PMID: 6880555].[Medline]
52. Fisher BL, Pennathur A, Mutnick JL, Little AG. Obesity correlates with gastroesophageal reflux. Dig Dis Sci. 1999;44:2290-4. [PMID: 10573376].[Medline]
53. Wajed SA, Streets CG, Bremner CG, DeMeester TR. Elevated body mass disrupts the barrier to gastroesophageal reflux; discussion 1018-9. Arch Surg. 2001;136:1014-8. [PMID: 11529823].
54. Nandurkar S, Locke GR 3rd, Fett S, Zinsmeister AR, Cameron AJ, Talley NJ. Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community. Aliment Pharmacol Ther. 2004;20:497-505. [PMID: 15339321].[Medline]
55. Kahrilas PJ. The role of hiatus hernia in GERD. Yale J Biol Med. 1999;72:101-11. [PMID: 10780571].[Medline]
56. El-Serag HB, Johanson JF. Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease. Scand J Gastroenterol. 2002;37:899-904. [PMID: 12229963].[Medline]
57. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med. 1991;151:448-54. [PMID: 1672062].
58. Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol. 1999;34:337-40. [PMID: 10365891].[Medline]
59. Kjellin A, Ramel S, Rössner S, Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol. 1996;31:1047-51. [PMID: 8938895].[Medline]
60. Frezza EE, Ikramuddin S, Gourash W, Rakitt T, Kingston A, Luketich J, et al. Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2002;16:1027-31. [PMID: 11984683].[Medline]
61. Jones KB Jr. Roux-en-Y gastric bypass: an effective antireflux procedure in the less than morbidly obese. Obes Surg. 1998;8:35-8. [PMID: 9562484].[Medline]
62. Caygill CP, Johnston DA, Lopez M, Johnston BJ, Watson A, Reed PI, et al. Lifestyle factors and Barrett's esophagus. Am J Gastroenterol. 2002;97:1328-31. [PMID: 12094845].[Medline]
63. Chak A, Lee T, Kinnard MF, Brock W, Faulx A, Willis J, et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut. 2002;51:323-8. [PMID: 12171951].
64. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology. 2002;123:461-7. [PMID: 12145799].[Medline]
This article has been cited by other articles:
![]() |
C. E. Lewis, K. M. McTigue, L. E. Burke, P. Poirier, R. H. Eckel, B. V. Howard, D. B. Allison, S. Kumanyika, and F. X. Pi-Sunyer Mortality, Health Outcomes, and Body Mass Index in the Overweight Range: A Science Advisory From the American Heart Association Circulation, June 30, 2009; 119(25): 3263 - 3271. [Full Text] [PDF] |
||||
![]() |
R. G. Sturmey, C. P. Wild, and L. J. Hardie Removal of red light minimizes methylene blue-stimulated DNA damage in oesophageal cells: implications for chromoendoscopy Mutagenesis, May 1, 2009; 24(3): 253 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y-C Lee, A M-F Yen, J J Tai, S-H Chang, J-T Lin, H-M Chiu, H-P Wang, M-S Wu, and T H-H Chen The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease Gut, February 1, 2009; 58(2): 174 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Benson, H. J. Baer, and D. C. Kaelber Trends in the Diagnosis of Overweight and Obesity in Children and Adolescents: 1999-2007 Pediatrics, January 1, 2009; 123(1): e153 - e158. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Peters and K. Mengersen Selective Reporting of Adjusted Estimates in Observational Epidemiology Studies: Reasons and Implications for Meta-analyses Eval Health Prof, December 1, 2008; 31(4): 370 - 389. [Abstract] [PDF] |
||||
![]() |
R M Zagari, L Fuccio, M-A Wallander, S Johansson, R Fiocca, S Casanova, B Y Farahmand, C C Winchester, E Roda, and F Bazzoli Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study Gut, October 1, 2008; 57(10): 1354 - 1359. [Abstract] [Full Text] [PDF] |
||||
![]() |
S J Chung, D Kim, M J Park, Y S Kim, J S Kim, H C Jung, and I S Song Metabolic syndrome and visceral obesity as risk factors for reflux oesophagitis: a cross-sectional case-control study of 7078 Koreans undergoing health check-ups Gut, October 1, 2008; 57(10): 1360 - 1365. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Kumanyika, E. Obarzanek, N. Stettler, R. Bell, A. E. Field, S. P. Fortmann, B. A. Franklin, M. W. Gillman, C. E. Lewis, W. C. Poston II, et al. Population-Based Prevention of Obesity: The Need for Comprehensive Promotion of Healthful Eating, Physical Activity, and Energy Balance: A Scientific Statement From American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (Formerly the Expert Panel on Population and Prevention Science) Circulation, July 22, 2008; 118(4): 428 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
D A Corley, A Kubo, T R Levin, G Block, L Habel, W Zhao, P Leighton, G Rumore, C Quesenberry, P Buffler, et al. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study Gut, June 1, 2008; 57(6): 727 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sadeghi, C. J. Bain, N. Pandeya, P. M. Webb, A. C. Green, D. C. Whiteman, and for the Australian Cancer Study Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1169 - 1178. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. El-Serag Role of obesity in GORD-related disorders Gut, March 1, 2008; 57(3): 281 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
D C Whiteman, S Sadeghi, N Pandeya, B M Smithers, D C Gotley, C J Bain, P M Webb, A C Green, and for the Australian Cancer Study Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus Gut, February 1, 2008; 57(2): 173 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Francois, J Roper, A J Goodman, Z Pei, M Ghumman, M Mourad, A Z O. de Perez, G I Perez-Perez, C-H Tseng, and M J Blaser The association of gastric leptin with oesophageal inflammation and metaplasia Gut, January 1, 2008; 57(1): 16 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Barlow and and the Expert Committee Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity: Summary Report Pediatrics, December 1, 2007; 120(Supplement_4): S164 - S192. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A Corley Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link? Gut, November 1, 2007; 56(11): 1493 - 1494. [Full Text] [PDF] |
||||
![]() |
E. H. Livingston, A. C. Elliott, L. S. Hynan, and E. Engel When Policy Meets Statistics: The Very Real Effect That Questionable Statistical Analysis Has on Limiting Health Care Access for Bariatric Surgery Arch Surg, October 1, 2007; 142(10): 979 - 987. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lagergren Body measures in relation to gastro-oesophageal reflux Gut, June 1, 2007; 56(6): 741 - 742. [Full Text] [PDF] |
||||
![]() |
D. A Corley, A. Kubo, and W. Zhao Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms Gut, June 1, 2007; 56(6): 756 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Beuther and E. R. Sutherland Overweight, Obesity, and Incident Asthma: A Meta-analysis of Prospective Epidemiologic Studies Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 661 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.D.H. Malnick and H. Knobler The medical complications of obesity QJM, September 1, 2006; 99(9): 565 - 579. [Full Text] [PDF] |
||||
![]() |
K. Kostikas, A. I. Papaioannou, K. I. Gourgoulianis, C. J. Etzel, S. Kachroo, H. Yanai, H. Yoshida, N. Tada, B. C. Jacobson, and C. A. Camargo Jr. BMI and Gastroesophageal Reflux in Women N. Engl. J. Med., August 24, 2006; 355(8): 848 - 850. [Full Text] [PDF] |
||||
![]() |
D. A. Beuther, S. T. Weiss, and E. R. Sutherland Obesity and Asthma Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 112 - 119. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Jacobson, S. C. Somers, C. S. Fuchs, C. P. Kelly, and C. A. Camargo Jr. Body-mass index and symptoms of gastroesophageal reflux in women. N. Engl. J. Med., June 1, 2006; 354(22): 2340 - 2348. [Abstract] [Full Text] [PDF] |
||||
![]() |
JournalScan Gut, November 1, 2005; 54(11): 1637 - 1637. [Full Text] [PDF] |
||||
Read all Rapid Responses